LI
SMMT icon

LRI Investments’s Summit Therapeutics SMMT Stock Holding History

LRI Investments’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.29K Hold
500
– – ﹤0.01% 1053
2026
Q1 		$9.48K Buy
+500
New +$8.09K ﹤0.01% 897

Other funds holding SMMT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
WMP
Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

LRI Investments's SMMT Position: Q2 2026 in Review

LRI Investments held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 500 shares worth $7.29K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

LRI Investments first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.48K in Q1 2026. 43 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • LRI Investments held 500 shares of Summit Therapeutics worth $7.29K as of Q2 2026.
  • LRI Investments left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1053 holding.
  • LRI Investments first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • LRI Investments's Summit Therapeutics position peaked at $9.48K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.